Logitech Nominates New Chairperson and Directors to Board; Proposes 10% Annual Increase for FY19 Dividend
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today outlined a number of proposals, approved by its board of directors, on which it will ask shareholders to vote at the Company’s annual general meeting (AGM). The proposals include:
- The election to the board of Guy Gecht, former chief executive officer of Electronics for Imaging Inc. (EFI), and Michael Polk, former president and chief executive officer of Newell Brands Inc.
- The election of Wendy Becker as Logitech’s new chairperson following the 2019 AGM. This follows a decision by Guerrino De Luca not to stand for re-election as chairperson when his current term ends. Guerrino De Luca will remain on the board, subject to his re-election as a member of the board.
- A 10 percent annual increase for Logitech’s FY 2019 dividend.
Logitech’s AGM will take place in Lausanne, Switzerland on September 4, 2019.
New Board Directors
Logitech’s board of directors will ask shareholders at the 2019 AGM to approve the election to the board of Guy Gecht, former chief executive officer of Electronics for Imaging Inc. (EFI), and Michael Polk, former president and chief executive officer of Newell Brands Inc.
Lung Yeh has decided not to stand for re-election to the board at the 2019 AGM when his current term ends. Lung Yeh has been a non-executive member of Logitech's board of directors since September 2015 and serves on Logitech's Audit Committee and Technology and Innovation Committee. Logitech communicated last week that Dimitri Panayotopoulos, a non-executive member of Logitech's board of directors since December 2014, had resigned for personal reasons, effective immediately. Dimitri Panayotopoulos served on Logitech’s Compensation Committee.
Guerrino De Luca, executive chairperson of Logitech, commented: “We send our gratitude and warm wishes to Lung, as we did to Dimitri, for his dedicated service to Logitech. He has been an integral part of the team that saw Logitech transform into a growth company and we wish him well for the future.
“For three decades, Guy Gecht has held senior roles in engineering and business strategy, in public companies and start-ups based in Silicon Valley and Israel. A former long-tenure chief executive officer of Electronics for Imaging, he led the transformation of EFI into a global leader in digital imaging and is currently a board member of Check Point Software Technologies. Michael Polk has spent more than thirty years in senior leadership roles in consumer multi-brand, multi-category companies like Unilever, Kraft Foods and, most recently, Newell Brands. He also serves on the board of Colgate-Palmolive Company. His global business acumen and strong background in companies with a portfolio of consumer brands will be a real asset. We are fortunate to have two such highly qualified and experienced nominees for the board. We warmly welcome them both at this exciting time for the team.”
New Logitech Chairperson
After more than twenty years serving Logitech, of which ten years were as executive chairperson of Logitech’s board of directors, Guerrino De Luca has decided not to stand for re-election as chairperson at the 2019 AGM when his current term ends. Now that Bracken Darrell has been chief executive officer for more than five years, Guerrino, with the agreement of the board, has identified this as the right time for change, allowing for a smooth transition of Guerrino’s role as chairperson. Logitech is executing on its strategy to be a design-focused, multi-brand, multi-category company and has delivered six consecutive years of innovation and growth. Guerrino will continue to serve Logitech as an executive member of the board, subject to his re-election.
The board of directors will ask shareholders at the 2019 AGM to elect Wendy Becker as Logitech’s new chairperson. Wendy Becker has been a non-executive member of Logitech's board of directors since September 2017, is the current chair of Logitech's Compensation Committee and serves on Logitech's Nominating Committee. Wendy has deep experience in strategy, brand marketing and design from her senior leadership roles, as well as diverse board and trustee leadership positions.
“It’s impossible to measure the contribution Guerrino has made to Logitech, over his first decade as CEO and his second as executive chairperson,” said Bracken Darrell, Logitech president and chief executive officer. “Under Guerrino’s direct leadership as CEO, Logitech had remarkably innovative and successful years. And then he did what many retiring CEOs consider impossible: he took a long-term view of the company’s potential and agreed to step into the role of chairperson. As chairperson he has been a highly constructive partner for me. In classic Guerrino fashion, he is again thinking long term and starting the transition to a new chairperson for the future. I’m delighted that Guerrino will remain with us as an executive board member.
“I am equally excited to continue my collaboration with Wendy - she is a great partner to me and has provided incredible value and insight during her time on the board. A global citizen, she brings a rare depth and breadth of senior experience in retail, technology, consumer goods and non-profit sectors, as a leader, consultant and board member. Logitech benefits from her unique track record of bringing large company experience to small companies, and the best of small companies to large ones. We will continue to benefit from her impressive leadership and broad global experience.”
Increased Annual Dividend
Logitech’s board of directors has approved and proposes an annual dividend for Fiscal Year 2019 of approximately CHF 0.73 per share* – an approximately 10 percent increase compared to Fiscal Year 2018. The gross aggregate dividend is subject to shareholder approval at Logitech's AGM in Lausanne, Switzerland on September 4, 2019.
If the dividend proposal is approved by shareholders at the Company's AGM, the approximate payment date for the dividend is expected to be September 20, 2019.
Logitech expects to publish its annual report to shareholders and its invitation for its 2019 AGM in July 2019. The Company also intends to file its preliminary proxy statement, which includes additional information regarding the nominees and other proposals for the AGM, with the U.S. Securities and Exchange Commission and post it on the Company's website at http://ir.logitech.com in July 2019.
About Logitech
Logitech designs products that have an everyday place in people's lives, connecting them to the digital experiences they care about. More than 35 years ago, Logitech started connecting people through computers, and now it’s a multi-brand company designing products that bring people together through music, gaming, video and computing. Brands of Logitech include Logitech, Ultimate Ears, Jaybird, Blue Microphones, ASTRO Gaming and Logitech G. Founded in 1981, and headquartered in Lausanne, Switzerland, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and on the Nasdaq Global Select Market (LOGI). Find Logitech at www.logitech.com, the company blog or @Logitech.
This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding: the election of new directors and chairperson, dividends, the timing of dividend payments, the timing of the AGM, and the timing of various filings. The forward-looking statements in this release involve risks and uncertainties that could cause Logitech's actual results and events to differ materially from those anticipated in these forward-looking statements, including, without limitation: if our product offerings, marketing activities and investment prioritization decisions do not result in the sales, profitability or profitability growth we expect, or when we expect it; the demand of our customers and our consumers for our products and our ability to accurately forecast it; if we fail to innovate and develop new products in a timely and cost-effective manner for our new and existing product categories; if we do not successfully execute on our growth opportunities or our growth opportunities are more limited than we expect; if sales of PC peripherals are less than we expect; the effect of pricing, product, marketing and other initiatives by our competitors, and our reaction to them, on our sales, gross margins and profitability; if our products and marketing strategies fail to separate our products from competitors’ products; if we do not fully realize our goals to lower our costs and improve our operating leverage; if there is a deterioration of business and economic conditions in one or more of our sales regions or operating segments, or significant fluctuations in exchange rates; we cannot ensure that we will continue to increase our dividend payments or to pay dividends at all; the effect of changes to our effective income tax rates. A detailed discussion of these and other risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in Logitech's periodic filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended March 31, 2019, available at www.sec.gov, under the caption Risk Factors and elsewhere. Logitech does not undertake any obligation to update any forward-looking statements to reflect new information or events or circumstances occurring after the date of this press release.
Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A and/or its affiliates in the U.S. and other countries. All other trademarks are the property of their respective owners. For more information about Logitech and its products, visit the company’s website at www.logitech.com.
(LOGIIR)
* Based on the number of shares outstanding as of March 31, 2019. The actual number may change as of the record date.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190702005677/en/
Contact information
Ben Lu
Vice President, Investor Relations - USA
+1 (510) 713-5568
Krista Todd
Vice President, Global Communications - USA
+1 (510) 713-5834
Ben Starkie
Corporate Communications - Europe
+41 (0) 79-292-3499
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom